Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Non-Hodgkin 12Lymphoma 12Recurrence 11Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia 9Leukemia, Biphenotypic, Acute 8Ovarian Neoplasms 7Neoplasms 7Lymphoma, Mantle-Cell 7Myeloproliferative Disorders 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 6Hodgkin Disease 6Hematologic Neoplasms 6Lymphoma, Follicular 5Immunoproliferative Disorders 5Immune System Diseases 5Lymphoproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Lymphatic Diseases 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Mesothelioma 3Lung Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × fludarabine × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡